About
Novel therapeutics that induce mechanisms of immune homeostasis and treat autoimmune diseases
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBiotech
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
70
By Phase
PHASE2: 2
By Status
RECRUITING: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT07095127Lead Sponsor
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
PHASE2Recruiting
10 participants
Started: Sep 30, 2025 · Completed: Dec 31, 2026
NCT07027111Lead Sponsor
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
PHASE2Recruiting
60 participants
Started: Apr 25, 2025 · Completed: Jun 30, 2028
Locations (1)
Headquarters
Menlo Park, CA, United States
Map
Loading map...